Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q6487096> ?p ?o }
Showing triples 1 to 32 of
32
with 100 triples per page.
- Q6487096 subject Q7240335.
- Q6487096 subject Q8220082.
- Q6487096 subject Q8672681.
- Q6487096 subject Q8934089.
- Q6487096 abstract "Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by nasal inhalation.Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. It is under clinical evaluations in other countries.".
- Q6487096 atcPrefix "none".
- Q6487096 casNumber "203120-17-6".
- Q6487096 fdaUniiCode "B408IW3GL5".
- Q6487096 iupacName "(4S,5R,6R)-5-acetamido-4-carbamimidamido-6-[(1R,2R)-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid".
- Q6487096 pubchem "502272".
- Q6487096 thumbnail Laninamivir.svg?width=300.
- Q6487096 wikiPageWikiLink Q1089532.
- Q6487096 wikiPageWikiLink Q1773974.
- Q6487096 wikiPageWikiLink Q425196.
- Q6487096 wikiPageWikiLink Q7240335.
- Q6487096 wikiPageWikiLink Q8220082.
- Q6487096 wikiPageWikiLink Q834390.
- Q6487096 wikiPageWikiLink Q8672681.
- Q6487096 wikiPageWikiLink Q8934089.
- Q6487096 atcPrefix "none".
- Q6487096 casNumber "203120".
- Q6487096 iupacName "-5".
- Q6487096 pubchem "502272".
- Q6487096 unii "B408IW3GL5".
- Q6487096 type ChemicalSubstance.
- Q6487096 type Drug.
- Q6487096 type ChemicalObject.
- Q6487096 type Thing.
- Q6487096 type Q8386.
- Q6487096 comment "Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by nasal inhalation.Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals and Daiichi Sankyo co-own Laninamivir.".
- Q6487096 label "Laninamivir".
- Q6487096 depiction Laninamivir.svg.